Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Sep;89(3):456–460. doi: 10.1111/j.1365-2249.1992.tb06980.x

A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera.

R Verheijen 1, B A de Jong 1, W J van Venrooij 1
PMCID: PMC1554469  PMID: 1325307

Abstract

An ELISA for the detection of anti-topoisomerase I autoantibodies in sera from patients with suspected or manifest rheumatic diseases is described. The antigen source used in this assay consists of a recombinant protein containing the last 695 C-terminal amino acid residues of human topoisomerase I (topo I). The sensitivity of the assay was 61%, while the specificity was more than 98%. Using this ELISA, 47 sera from scleroderma patients and immunopositive for anti-topo I antibodies, were screened for the presence of the isotypes IgG, IgA and IgM to topo I. Our finding that relatively high levels of IgA antibodies to topo I are present in most of the sera tested is consistent with the results of Hildebrandt et al. [1]. In addition, it is demonstrated that the IgG and IgA antibodies in a serum may recognize different epitope regions on the topo I polypeptide.

Full text

PDF
456

Images in this article

457Fig. 1
on p.457
459Fig. 3
on p.459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Claman H. N. On scleroderma. Mast cells, endothelial cells, and fibroblasts. JAMA. 1989 Sep 1;262(9):1206–1209. doi: 10.1001/jama.262.9.1206. [DOI] [PubMed] [Google Scholar]
  2. D'Arpa P., Machlin P. S., Ratrie H., 3rd, Rothfield N. F., Cleveland D. W., Earnshaw W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2543–2547. doi: 10.1073/pnas.85.8.2543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Guldner H. H., Szostecki C., Vosberg H. P., Lakomek H. J., Penner E., Bautz F. A. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma. 1986;94(2):132–138. doi: 10.1007/BF00286991. [DOI] [PubMed] [Google Scholar]
  4. Habets W. J., de Rooij D. J., Salden M. H., Verhagen A. P., van Eekelen C. A., van de Putte L. B., van Venrooij W. J. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol. 1983 Oct;54(1):265–276. [PMC free article] [PubMed] [Google Scholar]
  5. Hildebrandt S., Weiner E., Senécal J. L., Noell S., Daniels L., Earnshaw W. C., Rothfield N. F. The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies. Arthritis Rheum. 1990 May;33(5):724–727. doi: 10.1002/art.1780330515. [DOI] [PubMed] [Google Scholar]
  6. Kahaleh M. B. Vascular disease in scleroderma. Endothelial T lymphocyte-fibroblast interactions. Rheum Dis Clin North Am. 1990 Feb;16(1):53–73. [PubMed] [Google Scholar]
  7. Kallenberg C. G. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am. 1990 Feb;16(1):11–30. [PubMed] [Google Scholar]
  8. Kumar V., Kowalewski C., Koelle M., Qutaishat S., Chorzelski T. P., Beutner E. H., Jarzabek-Chorzelska M., Kolacinska Z., Jablonska S. Scl-70 antigen stability and its effect on antibody detection in scleroderma. J Rheumatol. 1988 Oct;15(10):1499–1502. [PubMed] [Google Scholar]
  9. Maul G. G., French B. T., van Venrooij W. J., Jimenez S. A. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5145–5149. doi: 10.1073/pnas.83.14.5145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Maul G. G., Jimenez S. A., Riggs E., Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8492–8496. doi: 10.1073/pnas.86.21.8492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Oldstone M. B. Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50(6):819–820. doi: 10.1016/0092-8674(87)90507-1. [DOI] [PubMed] [Google Scholar]
  12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  13. Reimer G. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 1990 Feb;16(1):169–183. [PubMed] [Google Scholar]
  14. Shero J. H., Bordwell B., Rothfield N. F., Earnshaw W. C. Antibodies to topoisomerase I in sera from patients with scleroderma. J Rheumatol Suppl. 1987 Jun;14 (Suppl 13):138–140. [PubMed] [Google Scholar]
  15. Shero J. H., Bordwell B., Rothfield N. F., Earnshaw W. C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science. 1986 Feb 14;231(4739):737–740. doi: 10.1126/science.3003910. [DOI] [PubMed] [Google Scholar]
  16. Studier F. W., Rosenberg A. H., Dunn J. J., Dubendorff J. W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990;185:60–89. doi: 10.1016/0076-6879(90)85008-c. [DOI] [PubMed] [Google Scholar]
  17. Tan E. M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93–151. doi: 10.1016/s0065-2776(08)60641-0. [DOI] [PubMed] [Google Scholar]
  18. Verheijen R., Kuijpers H., Vooijs P., Van Venrooij W., Ramaekers F. Distribution of the 70K U1 RNA-associated protein during interphase and mitosis. Correlation with other U RNP particles and proteins of the nuclear matrix. J Cell Sci. 1986 Dec;86:173–190. doi: 10.1242/jcs.86.1.173. [DOI] [PubMed] [Google Scholar]
  19. Verheijen R., Van den Hoogen F., Beijer R., Richter A., Penner E., Habets W. J., van Venrooij W. J. A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis. Clin Exp Immunol. 1990 Apr;80(1):38–43. doi: 10.1111/j.1365-2249.1990.tb06438.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Verheijen R., de Jong B. A., Oberyé E. H., van Venrooij W. J. Molecular cloning of a major CENP-B epitope and its use for the detection of anticentromere autoantibodies. Mol Biol Rep. 1992 Feb;16(1):49–59. doi: 10.1007/BF00788753. [DOI] [PubMed] [Google Scholar]
  21. Weiner E. S., Earnshaw W. C., Senécal J. L., Bordwell B., Johnson P., Rothfield N. F. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum. 1988 Mar;31(3):378–385. doi: 10.1002/art.1780310309. [DOI] [PubMed] [Google Scholar]
  22. Wollersheim H., Thien T., Hoet M. H., Van Venrooy W. J. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest. 1989 Dec;19(6):535–541. doi: 10.1111/j.1365-2362.1989.tb00271.x. [DOI] [PubMed] [Google Scholar]
  23. de Rooij D. J., van de Putte L. B., Habets W. J., Verbeek A. L., van Venrooij W. J. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases. Scand J Rheumatol. 1988;17(5):353–364. doi: 10.3109/03009748809105271. [DOI] [PubMed] [Google Scholar]
  24. van Venrooij W. J., Stapel S. O., Houben H., Habets W. J., Kallenberg C. G., Penner E., van de Putte L. B. Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest. 1985 Mar;75(3):1053–1060. doi: 10.1172/JCI111767. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES